当前位置: 首页 > 期刊 > 《世界华人消化杂志》 > 2005年第9期
编号:10692867
健脾法为基础的中医药干预对胃癌预后的影响
http://www.100md.com 2005年5月1日 《世界华人消化杂志》 2005年第9期
     赵爱光,杨金坤, 郑坚, 沈克平, 上海中医药大学附属龙华医院肿瘤一科 上海市 200032

    蔡泳, 第二医科大学公共卫生学院预防医学教研室 上海市 200025

    赵爱光,女, 1968-04-28生, 上海人,汉族.2001年上海中医药大学博士,副主任医师, 主要从事肿瘤临床和中医药防治消化道肿瘤的研究工作.

    上海市科委青年科技启明星计划资助项目,No. 02QB14043

    上海市教委研究基金资助项目,No. 01C06

    通讯作者:赵爱光, 200032, 上海市徐汇区宛平南路725号, 上海中医药大学附属龙华医院肿瘤一科. aiguang@hotmail.com
, 百拇医药
    电话:021-64385700 传真: 021-64398310

    收稿日期:2005-01-21 接受日期: 2005-02-16

    Effect of Chinese Jianpi herbs on prognosisof gastric cancer

    Ai-Guang Zhao, Yong Cai, Jin-Kun Yang, Jian Zheng, Ke-Ping Shen

    Ai-Guang Zhao,Jin-Kun Yang, Jian Zheng, Ke-Ping Shen, Department of Oncology LonghuaHospital, Shanghai University of Traditional Chinese Medicine, Shanghai200032, China
, 百拇医药
    Yong Cai, School of Public Health, the Second Medical University ofShanghai, Shanghai 200025, China

    Supported by Shanghai Science and Technique Ministerial Foundation,No. 02QB14043; and Shanghai High-Education Bureau Foundation, No. 01C06

    Correspondence to: Dr. Ai-Guang Zhao, Department of Oncology,Longhua Hospital, Shanghai University of Traditional Chinese Medicine, 725Wanping South Road, Shanghai 200032, China. aiguang@hotmail.com
, 百拇医药
    Received: 2005-01-21 Accepted:2005-02-16

    Abstract

    AIM:
To evaluate the effect of Chinese jianpi herbal recipe WeiChang An (WCA) on the prognosis of gastric cancer.

    METHODS: Univariate and Cox regressions were applied to analyze theinfluence of the clinical, pathological and therapeutical variables on theprognosis of 166 gastric cancer patients.
, 百拇医药
    RESULTS: In univariate analysis, the significant prognostic factorswere the site of the tumor, the TNM stage, surgery, chemotherapy and WCA.Multivariate analysis suggested that the TNM stage, radical resection, andWCA were independent prognostic factors. Patients who received WCAdemonstrated better prognosis independent of other prognostic factors inmultivariate analysis. The odds ratios [Exp(B)] of stage II, III and IVwere 0.091 (95% CI: 0.028-0.294), 0.038 (95% CI: 0.008-0.175) and 0.303(95% CI: 0.152-0.603), respectively. Exp(B) of WCA was 3.575 (95% CI:1.768-7.228). The site of the tumor and chemotherapy had no influence onsurvival in multivariate analysis (P>0.05).
, 百拇医药
    CONCLUSION: Cox regression analysis is a proper statistical methodfor the evaluation of the effectiveness of Traditional Chinese Medicinetherapy on gastric cancer. The Chinese jianpi herbal recipe WCA hasimportant value for improving the prognosis of gastric cancer.

    Key Words: Jianpi herbal recipe; Gastric cancer; Prognosis

    Zhao AG, Cai Y, Yang JK, Zheng J, Shen KP. Effect of Chinese Jianpiherbs on prognosis of gastric cancer. Shijie Huaren Xiaohua Zazhi 2005;13(9):1055-1058
, http://www.100md.com
    摘要

    目的:
探讨比例风险模型(Cox模型)在中医药治疗胃癌疗效评价中的运用,研究健脾法为基础的中医药治疗对胃癌预后的影响作用.

    方法:采用单因素及Cox多因素回归分析了166例胃癌患者临床病理因素及治疗措施对预后的影响.

    结果:单因素分析表明,胃癌预后与肿瘤原发部位、临床病理分期、手术方式、化疗及健脾法为基础的中药胃肠安治疗相关.Cox多因素回归分析表明:临床病理分期、手术方式及中药胃肠安治疗是影响胃癌预后的独立因素.临床病理分期中以Ⅰ 期为参照,Ⅱ期、Ⅲ 期及Ⅳ期的相对危险度分别为0.091、0.038及0.303;手术方式中以根治术为参照,姑息切除术改道及探查术的相对危险度分别为0.054、0.128;中药胃肠安的相对危险度为3.575.而肿瘤原发部位、化疗则未显示为独立预后因素(P>0.05).
, http://www.100md.com
    结论:比例风险模型在中医药治疗胃癌的疗效评价中是适合和有价值的方法;健脾法为基础的中医药治疗是改善胃癌预后的有效干预措施.

    关键词:健脾法;胃癌; 预后

    赵爱光,蔡泳, 杨金坤,郑坚,沈克平. 健脾法为基础的中医药干预对胃癌预后的影响.世界华人消化杂志 2005;13(9):1055-10581 Otsuji E, Yamaguchi T, Sawai K, Hagiwara A, Taniguchi H, TakahashiT. Recent advances in surgical treatment have

    improved the survival of patients withgastric carcinoma. Cancer 1998;82:1233-1237
, http://www.100md.com
    2 Nakajima T, Nashimoto A, Kitamura M, Kito T, Iwanaga T, OkabayashiK, Goto M. Adjuvant mitomycin and fluorouracil

    followed by oral uracil plus tegafur inserosa-negative gastric cancer:a randomised trial. Gastric Cancer SurgicalStudy

    Group. Lancet 1999;354:273-277

    3 Cirera L, Balil A, Batiste-Alentorn E, Tusquets I, Cardona T,Arcusa A, Jolis L, Saigi E, Guasch I, Badia A, Boleda M.
, http://www.100md.com
    Randomized clinical trial of adjuvantmitomycin plus tegafur in patients with resected stage III gastriccancer.

    J Clin Oncol 1999;17:3810-3815

    4 Borie F, Rigau V, Fingerhut A, Millat B; French Association forSurgical Research. Prognostic factors for early gastric

    cancer in France: Cox regression analysisof 332 cases. World J Surg2004;28:686-691

    5 Zhang CW, Zou SC, Shi D, Zhao DJ. Clinical significance ofpreoperative regional intra-arterial infusion chemotherapy
, 百拇医药
    for advanced gastric cancer. World JGastroenterol 2004;10:3070-3072

    6 邱佳信, 贾筠生, 杨金坤, 郑坚, 郑嘉昌, 唐莱娣, 王楠, 沈克平, 庞惠芳, 计高荣, 钦丹萍, 李裕民, 周学义,骆学新, 刘铭升, 邱志芳, 曹林华, 董茂芝. 健脾法为主治疗晚期胃癌的探讨. 中医杂志 1992;8:23-25

    7 Yang JK, Zhen J, Shen KP. Clinical study on post-operativemetastasis prevention of progressive stage of gastric cancer

    by weichang'an. Zhongguo Zhongxiyi JieheZazhi 2003;23:580-582
, 百拇医药
    8 Shimada K, Ajani JA. Adjuvant therapy for gastric carcinomapatients in the past 15 years:a review of western and

    oriental trials. Cancer 1999;86:1657-1668

    9 王冠庭, 朱金水, 徐文玉, 王易, 周阿高. 扶正抗癌冲剂结合化疗治疗晚期胃癌的临床与实验研究.

    华人消化杂志 1998;6:214-218

    10 Bando E, Yonemura Y, Taniguchi K, Fushida S, Fujimura T, Miwa K.Outcome of ratio of lymph node metastasis in
, 百拇医药
    gastric carcinoma. Ann Surg Oncol 2002;9:775-784

    11 Bozzetti F, Bonfanti G, Morabito A, Bufalino R, Menotti V, AndreolaS, Doci R, Gennari L. A multifactorial approach for

    the prognosis of patients withcarcinoma of the stomach after curative resection. Surg Gynecol Obstet 1986;162:229-234

    12 Allgayer H, Heiss MM, Schhildberg FW. Prognostic factors in gastriccancer. Br J Surg 1997;84:1651-1664
, 百拇医药
    13 赵爱光, 杨金坤, 赵海磊. 健脾中药诱导人胃癌细胞裸小鼠移植瘤细胞凋亡的实验研究.

    世界华人消化杂志 2000;8:737-740

    14 赵爱光, 赵海磊, 杨金坤, 顾缨, 刘静, 唐莱娣. 人胃癌原位移植模型中宿主脾虚证的探讨.

    中国中西医结合消化杂志 2001;9:198-200

    15 Zhao AG, Zhao HL, Yan JK, Tang LD. Effects of Chinese Jianpi herbson cell apoptosis and related gene expression

    in human gastric cancer grafted ontonude mice. World J Gastroenterol 2002;8:792-796
, 百拇医药
    16 张成武, 邹寿椿, 裘华森, 赵大建, 施敦. 胃癌预后指标的多因素回归分析. 中华胃肠外科杂志 2002;5:113-116

    17 Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van CutsemE, Planker M, Santos JG, Piedbois P, Paillot B,Bodenstein H, Schmoll HJ, Bleiberg H,Nordlinger B, Couvreur ML, Baron B, Wils JA. Final results of arandomized

    phase III trial of sequentialhigh-dose methotrexate, fluorouracil, and doxorubicin versus etoposide,leucovorin, and
, 百拇医药
    fluorouracil versus infusionalfluorouracil and cisplatin in advanced gastric cancer:A trial of theEuropean Organization

    for Research and Treatment of CancerGastrointestinal Tract Group. J Clin Oncol 2000;18:2648-2657

    18 Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, YamamichiN, Miyata Y, Ikeda N, Yamamoto S, Fukuda H,Yoshida S; Japan Clinical OncologyGroup Study (JCOG9205). Randomized phase III trial of fluorouracil aloneversus
, 百拇医药
    fluorouracil plus cisplatin versusuracil and tegafur plus mitomycin in patients with unresectable, advancedgastric

    cancer: The Japan Clinical OncologyGroup Study (JCOG9205). J Clin Oncol 2003;21:54-59

    19 Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, Kang YK, Shin DB,Kim HT, Kim HJ. A phase III randomized study

    of 5-fluorouracil and cisplatinversus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracilalone in the
, 百拇医药
    treatment of advanced gastric cancer.Cancer 1993;71:3813-3818

    20 Hermans J, Bonenkamp JJ, Boon MC, Bunt AM, Ohyama S, Sasako M, Vande Velde CJ. Adjuvant therapy after curative

    resection for gastric cancer:Meta-analysis of randomized tails. J Clin Oncol 1993;11:1441-1447

    21 Earle CC, Maroun JA. Adjuvant chemotherapy after curative resectionfor gastric cancer in non-Asian patients: revisiting
, 百拇医药
    a meta-analysis of randomised trials.Eur J Cancer 1999;35:1059-1064

    22 Klein Kranenbarg E, Hermans J, van Krieken JH, van de Velde CJ.Evaluation of the 5th edition of the TNM classification

    for gastric cancer:improvedprognostic value. Br J Cancer 2001;84:64-71

    23 Kim JP, Kim YW, Yang HK, Noh DY. Significant prognostic factors bymultivariate analysis of 3926 gastric cancer
, http://www.100md.com
    patients. World J Surg 1994;18:872-877

    24 Weitz J, D'AngelicaM, Gonen M, Klimstra D, Coit DG, Brennan MF, Karpeh MS. Interaction of splenectomy and

    perioperative blood transfusions on prognosis of patients with proximal gastric and gastroesophageal junction cancer.

    J Clin Oncol 2003;21:4597-4603

    编辑 潘伯荣 审读 张海宁, 百拇医药( 赵爱光, 蔡 泳, 杨金坤, 郑 坚, 沈克平)
  • 查看PDF全文